

Review

Not peer-reviewed version

Lassa Fever: Critical Review and Prospects for Control

[Marianne E Besson](#) *, Michel Pepin , [Pierre-Alexandre Metral](#)

Posted Date: 22 July 2024

doi: 10.20944/preprints2024071745.v1

Keywords: neglected tropical disease; emerging disease; zoonosis; viral haemorrhagic fever; Lassa Fever; global health



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Review

Lassa Fever: Critical Review and Prospects for Control

Marianne E Besson ^{1,*}, Michel Pepin ² and Pierre-Alexandre Metral ³

¹ Department of Public Health, Royal Veterinary College, London, United-Kingdom, mbesson19@rvc.ac.uk

² Department of Virology and Infectiology, VetAgro Sup Lyon University, Marcy L'Etoile, France, michel.pepin@vetagro-sup.fr

³ Department of Geography, Grenoble Alpes University, Grenoble, France pierre-alexandre.metral@umr-pacte.fr

* Correspondence: mbesson19@rvc.ac.uk ; Tel.: +33689831628

Abstract: Lassa Fever is a deadly viral haemorrhagic disease, causing annually several hundreds of deaths in the Gulf of Guinea. This zoonotic disease is primarily transmitted to humans by rodents of the genus *Mastomys*, while secondary interhuman transmission accounts for approximately 20% of cases. Although this disease has been endemic in rural zones of the Gulf for hundreds of years, it is also characterised by epidemic outbreaks in the dry season, responsible for heavy death tolls. No licensed vaccine or satisfying treatment is currently available. Disease management is hindered by the incomplete knowledge of the epidemiology and distribution of the disease, resulting from an inadequate health and surveillance system. Additional scientific constraints such as the genetic diversity of the virus and the lack of understanding of the mechanisms of immune protection complexify the development of a vaccine. The intricate socio-economic context in the affected regions, and the lack of monetary incentive for drug development, allow the disease to persist in some of West Africa's poorest communities. The increase in the number of reported cases and in the fatality rate, the expansion of the endemic area, as well as the threat Lassa Fever represents internationally should urge the global community to work on the disease control and prevention. The disease control requires collaborative research for medical countermeasures and tailored public health policies. Lassa Fever, created by the interconnection between animals, humans, and ecosystems, and embedded in an intricate social context, should be addressed with a 'One Health' approach. This article provides an overview of Lassa Fever, focusing on Nigeria, and discusses the perspectives for the control of disease.

Keywords: neglected tropical disease; emerging disease; zoonosis; viral haemorrhagic fever; Lassa Fever; global health

1. Lassa Fever: Virus and Disease

Lassa Fever (LF) is a zoonotic haemorrhagic fever caused by Lassa virus (LASV), an enveloped single-stranded RNA virus belonging to the *Arenaviridae* family. LASV shows a high genetic variability, that comes mainly from transcription errors, although intrasegmental or intersegmental recombinations may also occur [1,2]. This high genetic diversity, with a nucleotide diversity up to 32% (Andersen et al. 2015) and 7 circulating lineages identified [3], complexifies control measures.

Immature dendritic cells and macrophages are the initial target cells of LASV [4]. Replication occurs within those cells without activation of immune response nor stimulation of T cells. Cytopathic effects (abnormal coagulation, endothelial barrier disruption, and dysfunctional platelet aggregation) and evasion of the immune response contribute to the processes by which viral infection develops and to the pathogenesis of the virus [5,6].

About eighty percent of infections are asymptomatic. In clinical infections, initial symptoms are usually unspecific: high fever, weakness, myalgia, chest and abdominal pain. It is often followed by

headaches, sore throat, vomiting and diarrhea. This non-specific clinical picture commonly leads to misdiagnoses, hindering patient management and transmission control [7]. In severe cases, the clinical course evolves to haemorrhages, facial swelling, central nervous system symptoms, multi-organ impairment and hypovolemic shock [8–10]. Traditionally, the average case fatality rate (CFR) for symptomatic patients was reported between 15% and 20% [8]. A comparison of confirmed cases to confirmed death by Yaro *et al.* [11] showed a CFR at 18.5% from 2017 to 2021. Although the CFR depends on the case definition (suspected, probable, or confirmed), the mortality rate has arguably been high over the past years. Taking into account only the confirmed and probable cases, the CFR in Nigeria was of 29.5% from December 2016 to December 2017 [12] and 29.2% in the 2018 epidemics [13], with 191 deaths over the year [14]. An even deadlier epidemic was reported in Liberia over the first half of 2023, with a 30% CFR [15]. Fatality rate can achieve 50% in hospitalised patients [16]. The case fatality per infection is lower, estimated around 1 to 2% [17,18], even if a more thorough assessment of the prevalence of asymptomatic LASV infection is needed.

Ribavirin is used to treat patients but must be given early in the clinical course [19]. Despite its administration, the CFR remains as high as 15% in hospitalised cases [20]. It is also highly toxic [21]. No vaccine is available, although several vaccine candidates have given promising results in preclinical trials [22]. Four candidates have been advanced into Phase I clinical trials [23], and the first Phase II clinical trial has started in April 2024.

Rodents of the species *Mastomys natalensis* (family of *Muridae*) also called multimammate rats, form the primary reservoir of the virus. They were identified through field studies after a large outbreak in Sierra Leone in 1972 [24]. Zoonotic infection, via indirect or direct contact with rats, accounts for eighty to ninety five percent of the cases [25–27]. A secondary interhuman transmission is possible, mainly via direct contact with blood and body fluids [28].

The multimammate rat is a peri-domestic, commensal species, highly abundant in rural zones. It is well adapted to anthropised territories as it prospers in cultivated lands and inside habitations [29]. It shows a wide distribution across Sub-Saharan Africa. The characteristics of traditional houses and granaries facilitate allow rodents to easily access them (Figure 1). Promiscuity with rats is a feature of daily life in rural areas of the Gulf of Guinea.



Figure 1. Architectural design and materials of traditional huts and granaries in Northern Nigeria facilitate rodent infestation.

2. A Devastating Disease in West Africa

LF is both endemic and epidemic in the Gulf of Guinea. Two areas of endemicity have classically been described: the region of the Mano River (Guinea, Sierra Leone, Liberia), and Nigeria. However, it is now acknowledged that the disease exists in other West African countries [27]. LF is estimated

to cause between 300 000 and 500 000 cases and 5000 to 6000 deaths annually [30]. However, no precise data can be obtained due to the lack of surveillance, as it mainly affects socio-economically deprived communities in isolated rural zones [31].

The disease burden is especially severe among pregnant women. In a hospital in Sierra Leone, a 30% CFR was observed among 40 women in the third trimester of pregnancy [32]. Abortions are also frequently described: 51 abortions out of 68 women followed by Price *et al.* [33]. LF can induce unilateral or bilateral sensorineural hearing loss in up to 30% of infected patients [34–36]. Because only limited treatment options, if any, are available for deafness in the affected countries, this represents a major liability for social and professional reintegration – even more in countries where deafness is sometimes considered as a sign of intellectual deficit [37]. It is also strongly suspected that LF can generate depression and psychosis [38,39]. Economic losses of the disease – direct and indirect cost, opportunity cost – have never been evaluated. Mateer and co-authors [36] suggest that deafness only (all causes included) cost 43 million dollars annually to Nigeria.

3. An Emerging Disease

LF was first described in the medical literature in the 1920s, under the name “savanna typhus”, as a disease causing prolonged fever, severe headache, neurological signs, hypotension, shock and multi-organ failure, with a high CFR (50%). In the following decades, both sporadic cases and outbreaks (notably among health care workers) were frequently reported in West Africa [40]. Lassa virus was identified in 1969, when a contaminated nurse was repatriated in the USA [41]. However, phylogenetic studies showed that LASV probably originated in Nigeria more than a thousand years ago. The virus subsequently spread to neighboring countries between 300 and 500 years ago, through human migrations during the colonial period [42,43]. Its recent emergence in Mali and the Ivory Coast has been attributed to forced displacements of populations caused by the Sierra Leone civil war (1991 – 2002) [44].

Since 2016, outbreaks annually hitting Nigeria in the dry season have intensified. In 2020, the deadliest outbreak in decades was recorded in the country. Over the year, 6732 suspected and 1181 confirmed cases were reported nationwide, with 224 deaths [45]. In 2023, that record was sadly surpassed: 9155 suspected cases were reported, 1270 cases were confirmed, with 227 deaths among those. Twenty-eight Nigerian states out of 36 were affected [46]. As of 30 June 2024, 7 817 suspected cases and 168 deaths were reported since the beginning of the year in Guinea, Liberia and Nigeria [47]. This surge over the years also reflects an increase in surveillance and diagnosis.

Meanwhile, an expansion of the endemic zone has been witnessed in the past decade, with the emergence of new lineages in previously unaffected countries (for instance Ghana, Ivory Coast or Togo) [43,48]. Benin, Burkina Faso, Ghana, Ivory Coast, Mali, Togo are now known as endemic countries, not only because of serological evidence of LF in humans [49], but also because of confirmed autochthonous primary infections [27,50,51] (Figure 2). It is alarming to observe that often, knowledge about the endemic zone is gained when Western travelers contract the disease [52,53].




Figure 2. Distribution map showing the numbers of reported clinical cases of LF in 2016 and 2023 in the countries of the endemic zone (estimated numbers only) [54].

4. Mapping the Spatial Distribution of Lassa Fever

For disease management, it is crucial to map the at-risk areas of Lassa zoonotic transmission. The endemicity area of Lassa Fever might extend beyond the regions where human cases have previously been described. First, LASV circulation in rodents has been evidenced in areas where human cases have not yet been reported [43,55]. The reservoir *Mastomys natalensis* has the widest distribution of all African rodents, due to its ecological tolerance and adaptability [56,57], as well as its high reproductive capacity. However, the *Mastomys* clade in West Africa is genetically differentiated from the others and could be the only one that carries the virus [58]. Indeed, LASV has

never been isolated east of the border between Nigeria and Cameroon, in a different clade of *M. natalensis* [59]. Opening ecological corridors (for instance through deforestation) could facilitate the movement of the virus-bearing *Mastomys* populations [60].

Besides, other species have been evidenced to carry the virus, such as *Rattus rattus* et *Mus minutoides* [61,62], as well as species from several other genera of rodents [63,64] - although it is still unknown whether the virus can sustain long-term infection in these species [65]. As these rodent species occupy different ecological niches, the area of zoonotic infection risk may extend, even more in the context of climate change and increased human mobility [66]. Through modelling of the ecological areas suitable for spillover events, it was estimated that 37.7 million people are at risk of zoonotic infection [55], and this number could drastically increase in the coming years with anthropic changes in West Africa [67]. While non-human primates are susceptible to the infection, LASV and anti-LASV antibodies have also been detected in domestic mammals such as dogs, goats, and pigs, confirming the host plasticity of the virus [68]. These data must urge us to expand research, to fully understand the epidemiological cycle of the virus, the host range, the extent of viral circulation in the reservoir species, and their involvement in the persistence of the virus in wildlife [69]. Active surveillance and surveys of the host species are necessary to prevent and monitor the emergence of the disease.

5. Why Lassa Fever Control Measures Are Failing

Characteristics inherent to the virus, such as its genetic diversity, complexify control measures. Seven circulating lineages have been identified so far [3], recent genetic analyses showed that selective pressure led to diversification and local adaption [70]. Virus characterization is incomplete and several lineages were discovered only recently [48,71,72].

Differences in pathogenicity between lineages impact the development of medical countermeasure. Strain Josiah (lineage IV) is the prototypic strain and has been used in many pre-clinical studies, but it is not necessarily the most pathogenic, as evidenced by challenge in guinea pigs [73]. The vaccines developed targeting this strain could exhibit reduced efficacy against other circulating strains [74].

Even if effective medical countermeasures existed, LF cannot be controlled through one-sided measures, such as massive distributions of prophylactics or drugs. The disease is indeed enrooted in an intricate socioeconomic context. To efficiently combat the emergence of LF, it is imperative to comprehend the political, anthropological, and economic processes that facilitate its existence.

The absence of adequate medical infrastructure and the disparities in healthcare accessibility within the affected countries undeniably pose a significant obstacle to the prevention and control of LF. In Nigeria for instance, above 95% of the population does not have health insurance [75,76]. As an estimated 84 million Nigerians live below the poverty line [77], the financial burden of medical bills is a barrier and only a small proportion of Nigerians benefit from health care [78]. The country presents some of the world worst healthcare indicators [79]. While the urban areas in the South of the country benefit from state-of-the art private hospitals (secondary and tertiary facilities), the vast majority of the rural areas lacks access to medical structure, and primary health care facilities are often decaying, understaffed, deficient in resources [18,78]. The population vulnerability, and the impact of an inadequate, inequitable health network, must be underscored when apprehending the LF issue. Civil unrest, terrorism in the Northeast of Nigeria as well as nationwide fraud and corruption prevent an efficient fight against the disease.

These disastrous observations for Nigeria are unfortunately similar in the other endemic countries: Liberia, Sierra Leone and Guinea respectively rank 178, 181 and 182 out of 191 countries in the world human capital index [80] and suffer from systematic corruption in health sectors [81].

Richmond and Bagloge [18] also described a fear of social stigma associated with the disease, which consequently dissuades affected individuals from consulting a doctor. Diseases are taboo in many Western African communities, and patients fear rejection from their community. Besides, a defiance towards Western medicine exists.

As above eighty percent of cases stems from zoonotic transmission, sensitization campaigns were organised to prevent people from hunting and eating multimammate rodents. They do not systematically reach the concerned populations [82], and their messages are often misinterpreted. For instance, through interviews with Sierra Leonean villagers, Bonwitt and co-authors [83] picked up a frequent misidentification of the reservoir (shrews were incriminated instead of the multimammate rats). The general lack of understanding of the attractiveness of rat consumption, and in return a distrust towards public health authorities (reinforced by the bushmeat ban in response to the Ebola crisis) further hindered the campaigns effectiveness [84].

Limiting secondary transmission is also challenging. The non-descript symptoms frequently result in a wrong identification of the disease by professional health workers. Woyessa and co-authors [85] emphasise that “clinicians [...], especially primary health facilities, need to consider LF as a differential diagnosis when the patient failed to respond to anti-malaria and broad-spectrum antibiotics”. Additionally, endemic zones do not have adequate laboratory capacities, which is a barrier to perform a prompt diagnosis and a confirmation of LASV infection [86].

While rapid diagnostic tests would be an asset, their development is impeded by the high genetic diversity. The pan-Lassa rapid diagnostic test, using a mixture of polyclonal antibodies against LASV recombinant proteins, showed high sensitivity and specificity for patients with a high virus load in a Nigerian specialist hospital setting [87]. It still needs to be tested on more lineages. Distribution to the affected areas remains an issue [88]. Similarly, insufficient supply in ribavirin, which often delays its administration, and limited resources for patient care, hamper cases management [89].

Many non-specialist health facilities also lack personal protective equipment [90]. Instances are also described where, although body protections were available, they were not worn by the health workers, notably when LF diagnosis has not been made yet [7]. Ebola epidemic in Liberia, Sierra Leone, Guinea led to a heavy death toll among specialist medical forces and weakened capacities for medical response. General practitioners must be sensitised to recognition of communicable diseases so that prophylactic measures can be enforced.

6. An Emerging Threat

Several factors contribute to the emergence of the disease. Genetic diversity of the sequenced isolates shows an increase in spillover phenomena [26], especially in the dry season [91]. The multimammate rat forms the dominant rodent species in human-disturbed habitats, in particular after fires [92,93]. Deforestation (notably through slash-and-burn farming) leads to the proliferation of *Mastomys* rats and increases rodent to human contact rates. Expansion of territories suitable for *M. natalensis* also open corridors between geographically distinct populations of rodents, initiating the transmission of LASV in previously disease-free populations [60]. Deforestation, changes in land use and disturbance of ecosystems have consequently been identified as key factors in LF current emergence. Climate change, through an increase in rainfalls in the Gulf of Guinea, is also expected to increase suitability for *M. natalensis* across the region and its reproductive capacity [94]. Models suggest that the number of spillover events could double in the coming decades [58]. Furthermore, mobility and globalisation increase the number of human-to-human transmissions and of exported cases [66].

LF holds the title for most frequently exported viral haemorrhagic disease, with 37 primary exported cases since 1969 (Figure 3) [95,96]. In 2022, three cases and one death were confirmed in the United Kingdom: the first person contracted the disease while traveling in Mali, and transmitted it to two family members upon return to the United Kingdom [96]. The long incubation period and the possibility, even low, of an asymptomatic transmission are additional risk factors for secondary propagation in non-endemic countries [97]. Several West African cities are travel hubs, and this interconnection facilitates the spread of haemorrhagic viral fevers [98].




Figure 3. Map of the LF exported cases (primary and secondary transmission) from 1969 to 2024.

Even though events presenting a risk of international propagation must be notified to the World Health Organisation (WHO), according to the 2005 International Health Regulations, delays or failures were detected. For instance, in 2016, an outbreak in Benin was not reported, leading to subsequent cases in Togo and in Germany [99,100]. Similarly, in November 2019, two Dutch healthcare professionals were contaminated while performing surgery on an infected patient in Sierra Leone and were repatriated. While the LASV infection was confirmed by RT-PCR on November 20, the Ministry of Health in Sierra Leone formally notified WHO of the ongoing epidemics only a few days later [53,101]. International Health Regulations' directives for notification of event do not appear in the official Nigerian guidelines for LF case management and infection control [102]. The lack of effective public health surveillance systems in the affected regions and the absence of active surveillance are arguably additional barriers to the disease containment [94].

Nevertheless, because LF is recognised to be a threat for the global community, it received increased international attention over the past decade. It features in the WHO R&D Blueprint list of priority diseases, requiring urgent research and development attention. The international community also aims at improving epidemic preparedness to the disease [103,104]. The Coalition for Epidemic Preparedness Innovations (CEPI) provides increased funding for research efforts [105], and supports programmes for vaccine research or rapid diagnostic tests development [106]. Additionally, CEPI initiated the largest prospective cohort and research capacity building study, the "Enable Lassa Research Programme" following above 23 000 participants in five West African countries (Benin, Guinea, Liberia, Sierra Leone) [107]. This initiative is a key step in strengthening the disease surveillance. It will also help prepare future field trials to assess efficacy and safety of vaccine or therapeutics [108].

7. Prospects for control of Lassa Fever

First, prospects for control dwell in development of both prophylactic and therapeutic medical countermeasures. Because of the lack of profitability of the market in the affected countries, there is little financial incentive for pharmaceutical industries to fund research and development initiatives for LF. Therefore, efforts mostly rely on public health institutions and non-governmental organisations [109]. Therapeutic options are currently limited to supportive care and to off-label use of ribavirin, effective only in the early stage of the disease and potentially harmful. New drugs are being investigated for LF management, as reviewed by Garry [110] and Melnik [111]. Favipiravir successfully treated LASV infection in mice [112] and in macaques [113]. However, the first report of use in two human patients in Togo described nausea and worsening transaminitis, forcing the discontinuation of therapy [114]. Comparatively, the viral entry inhibitor LHF-535 was well tolerated in healthy human volunteers. It showed efficacy in guinea pigs [115], and had an adequate pharmacokinetics profile, but its performance in diseased patients is yet to be evaluated [116]. Immunotherapy offers promising prospects: Arevirumab-3, a combination of three monoclonal antibodies, protected macaques against parenteral challenge with both lineage II and III LASV isolates [117] and mucosal challenge with an isolate from lineage II [118]. Challenges remain, such as the need for protection against different circulating lineages with various pathogenicity. Similarly, the safety is to be assessed in patients with comorbidities, immunodeficiencies, undernourished or in poor health condition. The first clinical trial is to be set in West Africa, relying on LF specialized treatment centers in Nigeria (such as the Irrua Specialist Teaching Hospital), to identify and efficiently test new drugs candidates [119]. This initiative, launched by a new international consortium of public institutions, INTEGRATE, demonstrates the international will to pro-actively tackle the disease. The question of conveyance and broad availability of drugs in the affected areas, corroded by conflicts, with inadequate and unsafe transport network, remains unsolved. This is even more crucial as treatment must be initiated early in the disease course to be effective, and therefore should be available in primary health care facilities.

Regarding vaccines, four candidates entered the clinical trials, as described in the review by Sulis, Peebles and Basta [120]: one recombinant measles-vectored LF (MV-LASV) candidate, two candidates using a recombinant vesicular stomatitis virus platform (rVSV-LASV), and one DNA-based candidate. All initiatives are funded by CEPI. MV-LASV showed satisfactory safety and immunogenicity in healthy patients in the Phase I human trial [121]. The rVSV-LASV candidate developed by the International AIDS Vaccine Initiative (IAVI) was also well-tolerated in cohorts from Liberia and from the United States, in the Phase I trial. It elicited robust immune responses, persisting at least one year after vaccination [122]. This candidate has now been advanced into the first-ever Phase II human trial for LF, currently ongoing in Nigeria [123]. Results of Phase I trials for the second rVSV vaccine candidate (developed by Emergent BioSolutions Inc) [124] and for the DNA-based vaccine [125] are to date unpublished.

Because delivery to the affected areas will be complex, several companies are working on reducing the need for cold chain during delivery or storage [126]. However, as highlighted by Leach and Fairfield [127], the challenge is not only to address the “supply-side”, but also to prepare the “demand-side”. How will the population accept these medical measures? Nigeria has a history of vaccine refusal, stemming from the distrust towards Western health system. In 2003, at the instigation of religious community leaders, five northern states in Nigeria banned the administration of the polio vaccine, claiming that the vaccine was a “Western plot to sterilise women in Nigeria”, or contained human immunodeficiency virus [128].

Therefore, success of LF prevention and control programs depends on the degree to which they will include the social perceptions and culture of the target groups. For a vaccine to be accepted, local perspectives and knowledge should be recognised, and trust should be built with affected communities. The Strategic Advisory Group of Experts (SAGE) on Immunization recommends a multi-component strategy to overcome vaccine hesitancy, including mapping of the factors underlying the hesitancy, impactful communication, and education about vaccines in young

individuals. Overall, a collaborative approach should be encouraged rather than top-down directives [129].

Similarly, availability of a drug does not mean that diseased persons will seek medical help. To ensure that the affected population will consult, understanding the relationship of affected communities to health, and fighting the caveats of the health system, will be essential [78]. 'Healthcare hesitancy' and the stigma around disease are being more commonly acknowledged, as larger initiatives are now conducted to better characterize the incidence of LF [108]. Understanding local practices will also help limit primary contamination and interhuman transmission.

The 'One Health' paradigm reflects the interconnection between human health, animal health and ecosystem health. Above 60% of emerging infectious diseases are of zoonotic origin [130,131], as epitomised by the COVID-19 pandemic. Besides, the ecosystem changes driving LF emergence (deforestation, urbanization, globalization, climate change) potentiate the risk of emergence of many other zoonotic pathogens [132–134]. Therefore, recognizing this interrelationship is critical to effectively contend with new health threats [135]. In a broader sense, One Health refers to the understanding and integration of the underlying social, economic, and political dimensions of disease [136]. While policy makers cannot hold sway over the general socio-economic and politic context, some practical solutions have been brought forward, to address the anthropogenic factors that allow the disease emergence and persistence. For instance, rodents thrive in poor sanitary conditions [94]. Sanitation policies, implemented while taking into account the cultural and ethnic specificities [137], are a cost-effective way to prevent LF as well as other scourges [138]. Rather than sectoral interventions and divided research or policy efforts, an integrated approach for surveillance and response, that may address multiple diseases, must be promoted [136].

LF control will be hard to achieve without general economic and sanitary development of the region and reinforcement of health systems. Sufficient resources and supplies in primary care centers, as well as appropriate training of first medical responders, are key to curb the disease progression. Political structures which often underlie zoonotic disease burden must be challenged [139]. Political commitment must be obtained for a sustained effort to achieve LF control. Regional and national leadership is key in the fight against LF, with crucial actors such as the Nigeria Centre for Disease Control, or the Ministries of Health of affected countries. Regional capacity-building for research is also essential [140]. For instance, the Economic Community of West African States (ECOWAS) Regulators and Ethics Committees project aims at empowering regional stakeholders in research initiatives and clinical trials.

At last, Cunningham and co-authors [136] recommend shifting the narrative, from a focus on outbreak control to addressing LF endemicity. Indeed, despite an increased international awareness in the past decade, LF remains a neglected tropical disease, which receives only limited funding and attention [141].

8. Conclusions

Lassa Fever, a deadly zoonotic viral haemorrhagic fever, exemplifies the intricate web of interactions between the health of animals, humans, and ecosystems. As the number of spillover events drastically increased in the past years, the disease poses a multifaceted challenge. It is both a devastating endemic burden in West Africa, and an emerging threat to the global community. Lassa Fever's emergence and persistence are driven by various ecological and anthropologic factors. The poverty and deep vulnerabilities of the affected population, the inequity in access to healthcare, the lack of sanitation and economic development in the afflicted regions, represent key factors hindering the disease control and prevention. In an endemic region ravaged by conflict and social unrest, a comprehensive, intersectional approach, that considers the complexity of the socio-economic context is essential. International cooperation for research should be reinforced to bridge knowledge gaps (ecology and transmission of the virus, genetic diversity and lineage distribution, accurate mapping of at-risk areas, correlate of immune protections) and to develop effective medical countermeasures. Active and passive surveillance must be strengthened for a better understanding of the epidemiology of the disease. To allow a quick diagnosis, more research institutions are needed in the endemic

region, and alternative methods (rapid diagnostic test) should be validated. Because LF is a neglected tropical disease and receives only limited funding, public health interventions ought to be guided by appropriate modelling to target the at-risk populations. Recent advancements, such as the enhancement of the surveillance system and the progress in vaccine development, provide promising prospects for control. A collaborative and sustained effort, led by scientific research, brings hope that the impact of Lassa Fever could be lessened in the Gulf of Guinea, and its global threat managed. Recognizing the multifaceted nature of Lassa Fever will enable the development of comprehensive strategies that not only tackle the disease but also reduce the risk of other emerging zoonotic diseases. **Author Contributions:** Conceptualization, investigation, Marianne Besson; writing—original draft preparation, Marianne Besson.; writing—review and editing, Michel Pepin and Marianne Besson.; visualization, Pierre-Alexandre Metral. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Data Availability Statement: No new data were created in this study. Data sharing is not applicable to this article. The raw data supporting the creation of the maps can be made available by the authors on request.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Emonet S, Lemasson JJ, Gonzalez JP, de Lamballerie X, Charrel RN. Phylogeny and evolution of old world arenaviruses. *Virology*. 2006 Jul 5;350(2):251–7.
2. Zapata JC, Salvato MS. Arenavirus Variations Due to Host-Specific Adaptation. *Viruses*. 2013 Jan 17;5(1):241–78.
3. Ibukun FI. Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development. *Viruses*. 2020 Mar 31;12(4):386.
4. Baize S, Kiplon J, Faure C, Pannetier D, Georges-Courbot MC, Deubel V. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. *J Immunol Baltim Md 1950*. 2004 Mar 1;172(5):2861–9.
5. Russier M, Pannetier D, Baize S. Immune Responses and Lassa Virus Infection. *Viruses*. 2012 Nov 5;4(11):2766–85.
6. Schaeffer J, Carnec X, Reynard S, Mateo M, Picard C, Pietrosemoli N, et al. Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells. *PLOS Pathog*. 2018 Nov 12;14(11):e1007430.
7. Dan-Nwafor CC, Ipadeola O, Smout E, Ilori E, Adeyemo A, Umeokonwo C, et al. A cluster of nosocomial Lassa fever cases in a tertiary health facility in Nigeria: Description and lessons learned, 2018. *Int J Infect Dis*. 2019 Jun 1;83:88–94.
8. Marrama E. Rapid Risk Assessment: Lassa fever in Nigeria, Benin, Togo, Germany and USA, 24 March 2016 [Internet]. 2016 Mar [cited 2023 Oct 22]. Available from: <https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-lassa-fever-nigeria-benin-togo-germany-and-usa-24-march>
9. Basler CF. Molecular pathogenesis of viral hemorrhagic fever. *Semin Immunopathol*. 2017 Jul;39(5):551–61.
10. Africa Centres for Disease Control and Prevention. Lassa Fever [Internet]. Africa CDC. 2018 [cited 2023 Dec 10]. Available from: <https://africacdc.org/disease/lassa-fever/>
11. Yaro CA, Kogi E, Opara KN, Batiha GES, Baty RS, Albrakati A, et al. Infection pattern, case fatality rate and spread of Lassa virus in Nigeria. *BMC Infect Dis*. 2021 Feb 5;21:149.
12. Nigeria Centre for Disease Control. Lassa fever situation report, epidemiological week 46. 24 November - 1 December, 2017 [Internet]. Abuja; 2017 [cited 2023 Dec 28]. Report No.: 46. Available from: <https://ncdc.gov.ng/diseases/sitreps/?cat=5&name=An%20update%20of%20Lassa%20fever%20outbreak%20in%20Nigeria>
13. Grace JUA, Egoh IJ, Udensi N. Epidemiological trends of Lassa fever in Nigeria from 2015-2021: A review. *Ther Adv Infect Dis*. 2021 Nov 29;8:20499361211058252.
14. Nigeria Centre for Disease Control. Lassa Fever situation report, epidemiological week 52. 24 December - 31 December 2018. [Internet]. Abuja; 2018. Report No.: 52. Available from: <https://ncdc.gov.ng/diseases/sitreps/?cat=5&name=An%20update%20of%20Lassa%20fever%20outbreak%20in%20Nigeria>
15. UK Health Security Agency (UKHSA), Emerging Infections and Zoonoses (EIZ) team. Infectious disease surveillance and monitoring for animal and human health: summary January to June 2023 [Internet]. GOV.UK. 2023 [cited 2023 Dec 28]. Available from: <https://www.gov.uk/government/publications/emerging-infections-monthly-summaries/infectious-disease-surveillance-and-monitoring-for-animal-and-human-health-summary-january-to-june-2023>

16. European Centre for Disease Prevention and Control. Lassa fever in the Netherlands ex Sierra Leone. 2019; Available from: https://www.ecdc.europa.eu/sites/default/files/documents/RRA-Lassa-fever-in-the-Netherlands-ex-Sierra-Leone_0.pdf
17. McCormick JB. Epidemiology and control of Lassa fever. *Curr Top Microbiol Immunol.* 1987;134:69–78.
18. Richmond JK, Baglole DJ. Lassa fever: epidemiology, clinical features, and social consequences. *BMJ.* 2003 Nov 29;327(7426):1271–5.
19. Eberhardt KA, Mischlinger J, Jordan S, Groger M, Günther S, Ramharter M. Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis. *Int J Infect Dis.* 2019 Oct 1;87:15–20.
20. World Health Organisation. Lassa Fever, Fact sheets [Internet]. Geneva; 2017 Jul [cited 2020 Oct 15]. Available from: <https://www.who.int/news-room/fact-sheets/detail/lassa-fever>
21. Bannister B. Viral haemorrhagic fevers imported into non-endemic countries: risk assessment and management. *Br Med Bull.* 2010;95:193–225.
22. Warner BM, Safronet D, Stein DR. Current research for a vaccine against Lassa hemorrhagic fever virus. *Drug Des Devel Ther.* 2018 Aug 14;12:2519–27.
23. Isaac AB, Karolina W, Temitope AA, Anuska R, Joanne E, Deborah A, et al. PROSPECTS OF LASSA FEVER CANDIDATE VACCINES. *Afr J Infect Dis.* 2022 Aug 17;16(2 Suppl):46–58.
24. Monath TP, Newhouse VF, Kemp GE, Setzer HW, Cacciapuoti A. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. *Science.* 1974 Jul 19;185(4147):263–5.
25. Oloniniyi OK, Unigwe US, Okada S, Kimura M, Koyano S, Miyazaki Y, et al. Genetic characterization of Lassa virus strains isolated from 2012 to 2016 in southeastern Nigeria. *PLoS Negl Trop Dis.* 2018 Nov 30;12(11):e0006971.
26. Kafetzopoulou LE, Pullan ST, Lemey P, Suchard MA, Ehichioya DU, Pahlmann M, et al. Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak. *Science.* 2019 Jan 4;363(6422):74–7.
27. World Health Organisation. Lassa fever - Nigeria [Internet]. WHO Disease Outbreak News. 2023 [cited 2023 Dec 10]. Available from: <https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON463>
28. Fisher-Hoch SP, Tomori O, Nasidi A, Perez-Oronoz GI, Fakile Y, Hutwagner L, et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. *BMJ.* 1995 Sep 30;311(7009):857–9.
29. du Plessis J, Russo I, Child M. A conservation assessment of Mastomys spp. *Child MF Roxburgh Linh San E Raimondo Davies-Most HT Ed Red List Mamm South Afr Swazil Lesotho.* 2016;
30. Schmaljohn C, Safronet D. Editorial overview: Lassa virus. *Curr Opin Virol.* 2019 Aug 1;37:vii–ix.
31. Simons D. Lassa fever cases suffer from severe underreporting based on reported fatalities. *Int Health.* 2023 Sep 1;15(5):608–10.
32. Shaffer JG, Grant DS, Schieffelin JS, Boisen ML, Goba A, Hartnett JN, et al. Lassa Fever in Post-Conflict Sierra Leone. *PLoS Negl Trop Dis.* 2014 Mar 20;8(3):e2748.
33. Price ME, Fisher-Hoch SP, Craven RB, McCormick JB. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. *BMJ.* 1988 Sep 3;297(6648):584–7.
34. Cummins D, McCormick JB, Bennett D, Samba JA, Farrar B, Machin SJ, et al. Acute sensorineural deafness in Lassa fever. *JAMA.* 1990 Oct 24;264(16):2093–6.
35. Liao BS, Byl FM, Adour KK. Audiometric comparison of Lassa fever hearing loss and idiopathic sudden hearing loss: evidence for viral cause. *Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg.* 1992 Mar;106(3):226–9.
36. Mateer EJ, Huang C, Shehu NY, Paessler S. Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden. *PLoS Negl Trop Dis.* 2018;12(2):e0006187.
37. McPherson B, Brouillette R. Audiology in developing countries. New York: Nova Science Publishers, Inc. *Audiology in Developing Countries.* 2008. 1 p.
38. Macher AM, Wolfe MS. Historical Lassa Fever Reports and 30-year Clinical Update. *Emerg Infect Dis.* 2006 May;12(5):835–7.
39. Okogbenin EO, Obagaye MO, Aweh BE, Eriyo WO, Okogbenin SA, Okokhere PO. One-Year Retrospective Review of Psychiatric Consultations in Lassa Fever, Southern Nigeria. *Emerg Infect Dis.* 2020 Dec;26(12):3091–3.
40. Monath TP. Lassa fever: review of epidemiology and epizootiology. *Bull World Health Organ.* 1975;52(4–6):577–92.
41. Frame JD, Jr JMB, Gocke DJ, Troup JM. Lassa Fever, a New Virus Disease of Man from West Africa. *Am J Trop Med Hyg.* 1970 Jul 1;19(4):670–6.
42. Andersen KG, Shapiro BJ, Matranga CB, Sealfon R, Lin AE, Moses LM, et al. Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. *Cell.* 2015 Aug 13;162(4):738–50.
43. Manning JT, Forrester N, Paessler S. Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage. *Front Microbiol.* 2015;6:1037.

44. Lalis A, Leblois R, Lecompte E, Denys C, Meulen J ter, Wirth T. The Impact of Human Conflict on the Genetics of *Mastomys natalensis* and Lassa Virus in West Africa. *PLOS ONE*. 2012 May 15;7(5):e37068.

45. Nigeria Centre for Disease Control. Lassa Fever situation report, epidemiological week 52. 27 December 2020 – 2 January 2021. [Internet]. Abuja; 2021 [cited 2023 Dec 10]. Report No.: 52. Available from: <https://ncdc.gov.ng/diseases/sitreps/?cat=5&name=An%20update%20of%20Lassa%20fever%20outbreak%20in%20Nigeria>

46. Nigeria Centre for Disease Control. Lassa Fever situation report, epidemiological week 52 [Internet]. Abuja; 2023. Report No.: 52. Available from: <https://ncdc.gov.ng/diseases/sitreps/?cat=5&name=An%20update%20of%20Lassa%20fever%20outbreak%20in%20Nigeria>

47. Africa Centres for Disease Control and Prevention. Africa CDC Weekly Event Based Surveillance Report, June 2024 [Internet]. 2024 Jun [cited 2024 Jul 21]. Report No.: Africa CDC Weekly Event Based Surveillance Report, 30 June 2024. Available from: <https://africacdc.org/download/africa-cdc-weekly-event-based-surveillance-report-june-2024/>

48. Whitmer SLM, Strecker T, Cadar D, Dienes HP, Faber K, Patel K, et al. New Lineage of Lassa Virus, Togo, 2016. *Emerg Infect Dis*. 2018 Mar;24(3):599–602.

49. Emmerich P, Thome-Bolduan C, Drosten C, Gunther S, Ban E, Sawinsky I, et al. Reverse ELISA for IgG and IgM antibodies to detect Lassa virus infections in Africa. *J Clin Virol Off Publ Pan Am Soc Clin Virol*. 2006 Dec;37(4):277–81.

50. Dzotsi E, Ohene SA, Asiedu-Bekoe F, Amankwa J, Sarkodie B, Adjabeng M, et al. The First Cases of Lassa Fever in Ghana. *Ghana Med J*. 2012 Sep;46(3):166–70.

51. Centres for Disease Control and Prevention. Outbreak Distribution Map | Lassa Fever | CDC [Internet]. 2014 [cited 2023 Dec 10]. Available from: <https://www.cdc.gov/vhf/lassa/outbreaks/index.html>

52. Atkin S, Anaraki S, Gothard P, Walsh A, Brown D, Gopal R, et al. The first case of Lassa fever imported from Mali to the United Kingdom, February 2009. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2009 Mar 12;14(10).

53. World Health Organisation. Weekly Bulletin on Outbreak and other Emergencies: Week 47: 18 - 24 November 2019. Weekly Bulletin on Outbreaks and other Emergencies World Health Organization. Regional Office for Africa. 2019; Available from: <https://iris.who.int/handle/10665/329974> Revue Weekly Bulletin on Outbreaks and other Emergencies

54. Africa Centres for Disease Control and Prevention. Africa CDC Weekly Event Based Surveillance Report, Feb 2024. 2024 Feb. Report No.: Africa CDC Weekly Event Based Surveillance Report, 17 Feb 2024.

55. Mylne AQN, Pigott DM, Longbottom J, Shearer F, Duda KA, Messina JP, et al. Mapping the zoonotic niche of Lassa fever in Africa. *Trans R Soc Trop Med Hyg*. 2015 Aug;109(8):483–92.

56. Colangelo P, Verheyen E, Leirs H, Tatard C, Denys C, Dobigny G, et al. A mitochondrial phylogeographic scenario for the most widespread African rodent, *Mastomys natalensis*: Phylogeography of *Mastomys natalensis*. *Biol J Linn Soc*. 2013 Apr;108(4):901–16.

57. Granjon L. *Mastomys natalensis*. IUCN Red List Threat species. 2016;

58. Redding DW, Moses LM, Cunningham AA, Wood J, Jones KE. Environmental-mechanistic modelling of the impact of global change on human zoonotic 2 disease emergence: A case study of Lassa fever. Macro-mechanistic modelling of zoonotic disease emergence. 2016 Jun 13 [cited 2020 Apr 17]; Available from: <https://www.repository.cam.ac.uk/handle/1810/256060>

59. Gibb R, Moses LM, Redding DW, Jones KE. Understanding the cryptic nature of Lassa fever in West Africa. *Pathog Glob Health*. 2017 Sep;111(6):276–88.

60. Adetola OO, Adebisi MA. Impacts of Deforestation on the Spread of *Mastomys natalensis* in Nigeria. 2019;11.

61. Wulff H, Fabiyi A, Monath TP. Recent isolations of Lassa virus from Nigerian rodents. *Bull World Health Organ*. 1975;52(4–6):609–13.

62. Demby AH, Inapogui A, Kargbo K, Koninga J, Kourouma K, Kanu J, et al. Lassa fever in Guinea: II. Distribution and prevalence of Lassa virus infection in small mammals. *Vector Borne Zoonotic Dis Larchmt N*. 2001;1(4):283–97.

63. Fichet-Calvet E, Becker-Ziaja B, Koivogui L, Günther S. Lassa Serology in Natural Populations of Rodents and Horizontal Transmission. *Vector-Borne Zoonotic Dis*. 2014 Sep 1;14(9):665–74.

64. Olayemi A, Oyeyiola A, Obadare A, Igbokwe J, Adesina AS, Onwe F, et al. Widespread arenavirus occurrence and seroprevalence in small mammals, Nigeria. *Parasit Vectors*. 2018 Jul 13;11(1):416.

65. Gryseels S, Baird SJE, Borremans B, Makundi R, Leirs H, Bellocq JG de. When Viruses Don't Go Viral: The Importance of Host Phylogeographic Structure in the Spatial Spread of Arenaviruses. *PLOS Pathog*. 2017 Jan 11;13(1):e1006073.

66. Lalis A, Wirth T. 11 - Mice and Men: an Evolutionary History of Lassa Fever. In: Grandcolas P, Maurel MC, editors. *Biodiversity and Evolution* [Internet]. Elsevier; 2018 [cited 2020 Feb 15]. p. 189–212. Available from: <http://www.sciencedirect.com/science/article/pii/B9781785482779500115>

67. Klitting R, Kafetzopoulou LE, Thiery W, Dudas G, Gryseels S, Kotamarthi A, et al. Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades. *Nat Commun.* 2022 Sep 27;13(1):5596.

68. Hippi AN, Ogunsanya OA, Ayinla AO, Sijuwola AE, Saibu FM, Akano K, et al. Lassa virus in novel hosts: insights into the epidemiology of lassa virus infections in southern Nigeria. *Emerg Microbes Infect.* 2024 Dec 31;13(1):2294859.

69. Arruda LB, Free HB, Simons D, Ansumana R, Elton L, Haider N, et al. Current sampling and sequencing biases of Lassa mammarenavirus limit inference from phylogeography and molecular epidemiology in Lassa fever endemic regions. *PLOS Glob Public Health.* 2023;3(11):e0002159.

70. Li Y. Genetic basis underlying Lassa fever endemics in the Mano River region, West Africa. *Virology.* 2023 Feb;579:128–36.

71. Olayemi A, Cadar D, Magassouba N, Obadare A, Kourouma F, Oyeyiola A, et al. New Hosts of The Lassa Virus. *Sci Rep.* 2016 May;6(1):25280.

72. Ehichioya DU, Dellicour S, Pahlmann M, Rieger T, Oestereich L, Becker-Ziaja B, et al. Phylogeography of Lassa Virus in Nigeria. *J Virol [Internet].* 2019 Oct 15 [cited 2019 Nov 11];93(21). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803284/>

73. Clegg JC, Lloyd G. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. *Lancet Lond Engl.* 1987 Jul 25;2(8552):186–8.

74. Hallam HJ, Hallam S, Rodriguez SE, Barrett ADT, Beasley DWC, Chua A, et al. Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. *NPJ Vaccines.* 2018;3:11.

75. Akokuwebe ME, Idemudia ES. A Comparative Cross-Sectional Study of the Prevalence and Determinants of Health Insurance Coverage in Nigeria and South Africa: A Multi-Country Analysis of Demographic Health Surveys. *Int J Environ Res Public Health.* 2022 Feb 4;19(3):1766.

76. Sasu. Nigeria: health insurance coverage, by area and gender | Statista [Internet]. 2022 [cited 2023 Dec 24]. Available from: <https://www.statista.com/statistics/1124757/health-insurance-coverage-in-nigeria-by-area-and-gender/>

77. World Bank. Nigeria Overview: Development news, research, data | World Bank [Internet]. The World Bank. 2023 [cited 2023 Dec 24]. Available from: <https://www.worldbank.org/en/country/nigeria/overview>

78. Okpani AI, Abimbola S. Operationalizing universal health coverage in Nigeria through social health insurance. *Niger Med J J Niger Med Assoc.* 2015;56(5):305–10.

79. Eke C. Nigeria - Healthcare [Internet]. Official Website of the USA International Trade Association. 2023 [cited 2023 Dec 24]. Available from: <https://www.trade.gov/country-commercial-guides/nigeria-healthcare>

80. United Nations Development Programme. HDR21-22_Statistical_Annex_HDI_Table.xlsx [Internet]. 2022 [cited 2023 Dec 27]. Available from: https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fhdr.undp.org%2Fsites%2Fdefault%2Ffiles%2F2021-22_HDR%2FHDR21-22_Statistical_Annex_HDI_Table.xlsx&wdOrigin=BROWSELINK

81. Onwujekwe O, Agwu P, Orjiakor C, McKee M, Hutchinson E, Mbachu C, et al. Corruption in Anglophone West Africa health systems: a systematic review of its different variants and the factors that sustain them. *Health Policy Plan.* 2019 Sep 1;34(7):529–43.

82. Wogu JO. Mass media awareness campaign and the prevention of the spread of Lassa fever in the rural communities of Ebonyi State, Nigeria: Impact evaluation. *J Public Health Afr [Internet].* 2018 Dec 21 [cited 2020 May 25];9(3). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379693/>

83. Bonwitt J, Kelly AH, Ansumana R, Agbla S, Sahr F, Saez AM, et al. Rat-atouille: A Mixed Method Study to Characterize Rodent Hunting and Consumption in the Context of Lassa Fever. *EcoHealth.* 2016 Jun 1;13(2):234–47.

84. Bonwitt J, Dawson M, Kandeh M, Ansumana R, Sahr F, Brown H, et al. Unintended consequences of the 'bushmeat ban' in West Africa during the 2013–2016 Ebola virus disease epidemic. *Soc Sci Med.* 2018 Mar 1;200:166–73.

85. Woyessa AB, Maximore L, Keller D, Dogba J, Pajibo M, Johnson K, et al. Lesson learned from the investigation and response of Lassa fever outbreak, Margibi County, Liberia, 2018: case report. *BMC Infect Dis.* 2019 Jul 11;19(1):610.

86. Schroeder LF, Amukele T. Medical laboratories in sub-Saharan Africa that meet international quality standards. *Am J Clin Pathol.* 2014 Jun;141(6):791–5.

87. Boisen ML, Uyigue E, Aiyepada J, Siddle KJ, Oestereich L, Nelson DKS, et al. Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak. *Sci Rep.* 2020 May 26;10(1):8724.

88. Mazzola LT, Kelly-Cirino C. Diagnostics for Lassa fever virus: a genetically diverse pathogen found in low-resource settings. *BMJ Glob Health [Internet].* 2019 Feb 7 [cited 2020 May 18];4(Suppl 2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407561/>

89. Akpede GO, Asogun DA, Okogbenin SA, Dawodu SO, Momoh MO, Dongo AE, et al. Caseload and Case Fatality of Lassa Fever in Nigeria, 2001–2018: A Specialist Center's Experience and Its Implications. *Front*

Public Health [Internet]. 2019 Jun 25 [cited 2020 Apr 5];7. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603170/>

90. Ijarotimi IT, Ilesanmi OS, Aderinwale A, Abiodun-Adewusi O, Okon IM. Knowledge of Lassa fever and use of infection prevention and control facilities among health care workers during Lassa fever outbreak in Ondo State, Nigeria. *Pan Afr Med J* [Internet]. 2018 May 24 [cited 2019 Nov 12];30. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125309/>

91. McKendrick JQ, Tennant WSD, Tildesley MJ. Modelling seasonality of Lassa fever incidences and vector dynamics in Nigeria. *PLoS Negl Trop Dis*. 2023 Nov 13;17(11):e0011543.

92. Avenant NL, Watson JP, Schulze E. Correlating small mammal community characteristics and habitat integrity in the Caledon Nature Reserve, South Africa. *Mammalia*. 2008 Sep 1;72(3):186–91.

93. MacFadyen DN, Avenant NL, Merwe M van der, Bredenkamp GJ. The Influence of Fire on Rodent Abundance at the N'washitshumbe Enclosure Site, Kruger National Park, South Africa. *Afr Zool*. 2012 Apr;47(1):138–46.

94. Balogun OO, Akande OW, Hamer DH. Lassa Fever: An Evolving Emergency in West Africa. *Am J Trop Med Hyg*. 2021 Feb;104(2):466.

95. Wolf T, Ellwanger R, Goetsch U, Wetzstein N, Gottschalk R. Fifty years of imported Lassa fever: a systematic review of primary and secondary cases. *J Travel Med*. 2020 Jul 14;27(4):taaa035.

96. World Health Organisation. Lassa fever – United Kingdom of Great Britain and Northern Ireland [Internet]. Disease Outbreak News. 2022 [cited 2023 Dec 27]. Available from: <https://www.who.int/emergencies/disease-outbreak-news/item/lassa-fever-united-kingdom-of-great-britain-and-northern-ireland>

97. Brosh-Nissimov T. Lassa fever: another threat from West Africa. *Disaster Mil Med* [Internet]. 2016 Apr 30 [cited 2020 May 6];2. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330145/>

98. Tuite AR, Watts AG, Kraemer MUG, Khan K, Bogoch II. Potential for Seasonal Lassa Fever Case Exportation from Nigeria. *Am J Trop Med Hyg*. 2019 Mar;100(3):647–51.

99. World Health Organisation. Lassa Fever – Germany [Internet]. Disease Outbreak News. 2016 [cited 2023 Dec 28]. Available from: <https://www.who.int/emergencies/disease-outbreak-news/item/23-march-2016-lassa-fever-germany-en>

100. World Health Organisation. Lassa Fever – Togo [Internet]. Disease Outbreak News. 2016 [cited 2023 Dec 28]. Available from: <https://www.who.int/emergencies/disease-outbreak-news/item/23-march-2016-lassa-fever-togo-en>

101. Njuguna C, Vandi M, Liyosi E, Githuku J, Wurie A, Njeru I, et al. A challenging response to a Lassa fever outbreak in a non endemic area of Sierra Leone in 2019 with export of cases to The Netherlands. *Int J Infect Dis*. 2022 Apr 1;117:295–301.

102. Ihekweazu C. National Guidelines for Lassa Fever case management [Internet]. Nigeria: National Centre for Disease Control; 2018. Available from: https://ncdc.gov.ng/themes/common/docs/protocols/92_1547068532.pdf

103. Mehand MS, Al-Shorbaji F, Millett P, Murgue B. The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. *Antiviral Res*. 2018 Nov 1;159:63–7.

104. World Health Organisation. Prioritizing diseases for research and development in emergency contexts [Internet]. 2023 [cited 2020 Jun 11]. Available from: <https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts>

105. Bernasconi V, Kristiansen PA, Whelan M, Román RG, Bettis A, Yimer SA, et al. Developing vaccines against epidemic-prone emerging infectious diseases. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2020;63(1):65–73.

106. CEPI. Testing the tests: Scientists seek out best on-the-spot diagnostics for deadly Nipah and Lassa | CEPI [Internet]. CEPI official website. 2024 [cited 2024 Jul 21]. Available from: <https://cepi.net//testing-tests-scientists-seek-out-best-spot-diagnostics-deadly-nipah-and-lassa>

107. Epidemic Preparedness Innovations. Enable Epi Study • Epidemic Preparedness Innovations [Internet]. The Global Health Network. 2024 [cited 2024 Jul 21]. Available from: <https://epi.tghn.org/epidemiology/epi-studies/>

108. Goios A, Varma A, Kagia C, Otiende M, Suykerbuyk P. Enable Lassa Research Programme Mid-term Workshop. Abuja, Nigeria; 2022.

109. Mueller-Langer F. Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research? *Health Econ Policy Law*. 2013 Apr;8(2):185–208.

110. Garry RF. Lassa fever - the road ahead. *Nat Rev Microbiol*. 2023 Feb;21(2):87–96.

111. Melnik LI. Lassa Virus Countermeasures. *Curr Top Microbiol Immunol*. 2023;440:111–45.

112. Oestereich L, Rieger T, Lüdtke A, Ruibal P, Wurr S, Pallasch E, et al. Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever. *J Infect Dis*. 2016 Mar 15;213(6):934–8.

113. Rosenke K, Feldmann H, Westover JB, Hanley PW, Martellaro C, Feldmann F, et al. Use of Favipiravir to Treat Lassa Virus Infection in Macaques. *Emerg Infect Dis*. 2018 Sep;24(9):1696.
114. Raabe VN, Kann G, Ribner BS, Morales A, Varkey JB, Mehta AK, et al. Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2017 Sep 1;65(5):855–9.
115. Cashman KA, Wilkinson ER, Posakony J, Madu IG, Tarcha EJ, Lustig KH, et al. Lassa antiviral LHF-535 protects guinea pigs from lethal challenge. *Sci Rep*. 2022 Nov 19;12(1):19911.
116. Amberg SM, Snyder B, Vliet-Gregg PA, Tarcha EJ, Posakony J, Bedard KM, et al. Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults. *Antimicrob Agents Chemother*. 2022 Nov 15;66(11):e0095122.
117. Cross RW, Heinrich ML, Fenton KA, Borisevich V, Agans KN, Prasad AN, et al. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus. *Proc Natl Acad Sci U S A*. 2023 Aug 22;120(34):e2304876120.
118. Cross RW, Fenton KA, Woolsey C, Prasad AN, Borisevich V, Agans KN, et al. Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus. *Cell Rep Med*. 2024 Feb 20;5(2):101392.
119. ALIMA. First-ever global alliance of researchers, health workers, and humanitarians join forces to fight the deadly Lassa fever virus - ALIMA - The Alliance for Medical Action [Internet]. 2024 [cited 2024 Jul 21]. Available from: <https://alima.ngo/en/press-releases/lassa-fever-alliance-virus/>
120. Sulis G, Peebles A, Basta NE. Lassa fever vaccine candidates: A scoping review of vaccine clinical trials. *Trop Med Int Health*. 2023;28(6):420–31.
121. Tschismarov R, Van Damme P, Germain C, De Coster I, Mateo M, Reynard S, et al. Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial. *Lancet Lond Engl*. 2023 Apr 15;401(10384):1267–76.
122. Baden M, Kieh L, Fitz-Patrick D, Diemert D, Mutua G. First Safety & Immunogenicity Data from a FIH, Placebo-controlled, Dose-escalation Trial of a Recombinant Vesicular Stomatitis Virus-based Lassa Fever Vaccine in Healthy Adults [Internet]. 2023 [cited 2024 Jul 21]; Chicago. Available from: https://www.iavi.org/wp-content/uploads/2023/11/C102_ASTMH_Poster_Chicago2023.pdf
123. Abiola A. Time to hope for a Lassa fever vaccine? [Internet]. GAVI, the Vaccine Alliance. 2024 [cited 2024 Jul 21]. Available from: <https://www.gavi.org/vaccineswork/time-hope-lassa-fever-vaccine>
124. Pan African Clinical Trials Registry. A Phase 1 Randomized, Blinded, Placebo Controlled, Dose-Escalation and Dosing Regimen Selection Study to Evaluate the Safety and Immunogenicity of rVSV-Vectored Lassa Virus Vaccine in Healthy Adults at Multiple Sites in West Africa [Internet]. Pan African Clinical Trials Registry. 2021 [cited 2024 Jul 21]. Available from: <https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=14618>
125. ClinicalTrials. No Study Results Posted | Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers | ClinicalTrials.gov [Internet]. ClinicalTrials.gov (US government). 2020 [cited 2024 Jul 21]. Available from: <https://clinicaltrials.gov/study/NCT03805984?tab=results>
126. Fahrni ML, Ismail IAN, Refi DM, Almeman A, Yaakob NC, Saman KM, et al. Management of COVID-19 vaccines cold chain logistics: a scoping review. *J Pharm Policy Pract*. 2022 Dec;15(1):1–14.
127. Leach M, Fairhead J. Understandings of immunization: some west African perspectives. *Bull World Health Organ*. 2008 Jun;86(6):418.
128. Michael CA, Ogbuanu IU, Storms AD, Ohuabunwo CJ, Corkum M, Ashenafi S, et al. An assessment of the reasons for oral poliovirus vaccine refusals in northern Nigeria. *J Infect Dis*. 2014 Nov 1;210 Suppl 1(Suppl 1):S125–130.
129. World Health Organisation. Report of the SAGE Working Group on Vaccine Hesitancy [Internet]. 2014 Nov [cited 2024 May 3]. Available from: https://www.asset-scienceinsociety.eu/sites/default/files/sage_working_group_revised_report_vaccine_hesitancy.pdf
130. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, et al. Global trends in emerging infectious diseases. *Nature*. 2008 Feb;451(7181):990–3.
131. Cutler SJ, Fooks AR, van der Poel WHM. Public Health Threat of New, Reemerging, and Neglected Zoonoses in the Industrialized World. *Emerg Infect Dis*. 2010 Jan;16(1):1–7.
132. Pepin M, Tordo N. Emerging and re-emerging animal viruses. Foreword. *Vet Res*. 2010;41(6):69.
133. El Amri H, Boukharta M, Zakham F, Ennaji MM. Emergence and Reemergence of Viral Zoonotic Diseases: Concepts and Factors of Emerging and Reemerging Globalization of Health Threats. *Emerg Reemerging Viral Pathog*. 2020;619–34.
134. Baker RE, Mahmud AS, Miller IF, Rajeev M, Rasambainarivo F, Rice BL, et al. Infectious disease in an era of global change. *Nat Rev Microbiol*. 2022 Apr;20(4):193–205.
135. Sinclair JR. Importance of a One Health approach in advancing global health security and the Sustainable Development Goals. *Rev Sci Tech Int Off Epizoot*. 2019 May;38(1):145–54.

136. Cunningham AA, Scoones I, Wood JLN. One Health for a changing world: new perspectives from Africa. *Philos Trans R Soc B Biol Sci.* 2017 Jun 5;372(1725):20160162.
137. Abubakar IR. Access to Sanitation Facilities among Nigerian Households: Determinants and Sustainability Implications. *Sustainability.* 2017 Apr;9(4):547.
138. Yaya S, Hudani A, Udenigwe O, Shah V, Ekhollenetale M, Bishwajit G. Improving Water, Sanitation and Hygiene Practices, and Housing Quality to Prevent Diarrhea among Under-Five Children in Nigeria. *Trop Med Infect Dis.* 2018 Apr 12;3(2):41.
139. Akokuwebe ME, Idemudia ES. Fraud within the Nigerian health system, a double threat for resilience of a health system and the response to the COVID-19 pandemic: a review. *Pan Afr Med J.* 2023 Jul 6;45:116.
140. Kalbarczyk A, Davis W, Kalibala S, Geibel S, Yansaneh A, Martin NA, et al. Research Capacity Strengthening in Sub-Saharan Africa: Recognizing the Importance of Local Partnerships in Designing and Disseminating HIV Implementation Science to Reach the 90–90–90 Goals. *AIDS Behav.* 2019 Sep 1;23(2):206–13.
141. Dalhat MM, Olayinka A, Meremikwu MM, Dan-Nwafor C, Iniobong A, Ntoimo LF, et al. Epidemiological trends of Lassa fever in Nigeria, 2018–2021. *PLOS ONE.* 2022 Dec 30;17(12):e0279467.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.